Physicians Cancer Chemotherapy

Review by eFreeware

Oncology moves quickly, and the gap between a printed drug manual and the current standard of care is measured in months. Physicians' Cancer Chemotherapy, from AtmosphereApps, is built for the people who feel that gap most: oncologists, hematology and oncology fellows, nurse practitioners and pharmacists who need drug-level detail without carrying a reference book. The developer describes it as a catalog of over 100 drugs and commonly used regimens covering all the major cancers, and that scope is the reason it exists.

What you get for the download is a structured reference rather than a treatment decision tool. Each agent comes with indications, doses and schedules, toxicities and special considerations, and there are chapters on regimens for the major cancers, antiemetic treatment for acute and delayed nausea and vomiting, and the basic principles of cancer drug therapy. I'd expect that combination to cover the questions that come up most often at the point of care: what is this drug used for, how is it dosed, what should I watch for, and what does it interact with.

The app has been around since May 2018 and was last updated in September 2025 with a maintenance release. It has more than 10,000 installs and a 4.7 average from 156 ratings, which suggests a small but satisfied professional audience rather than a mass-market one. That is roughly what I would expect for a niche clinical reference: few users, but users with a real reason to keep it installed.

Who tends to keep a drug reference on their phone

The clearest fit is a clinician who already knows how to interpret drug information and wants it in a compact form. Oncology fellows rotating through different services, advanced practice providers running treatment clinics, and pharmacists verifying regimens would all get use out of it. The content assumes a working vocabulary: doses, schedules, toxicity profiles and drug-drug interactions are the building blocks here, not background explanation.

It also suits people who teach or study the subject. The overview of cancer drug therapy principles and the diagrams of drug structures and pathways give a framework that a trainee can read alongside a syllabus. Someone preparing for rounds or a board-style discussion can use the regimen sections to see how agents are combined for a given cancer rather than memorizing single drugs in isolation.

Where I would be more cautious is with patients or family members looking for treatment guidance. The material is written for prescribers, and the developer's own framing places it alongside clinical cancer therapeutics. It is a professional reference, and it reads best in professional hands.

Because the app covers both on-label and off-label uses, it is also relevant to clinicians who work at the edges of standard practice, where the published evidence and the approved indication do not line up. Having that distinction visible in a reference is useful, since off-label use is common in oncology and often poorly documented in general drug databases.

What the drug catalog actually contains

The core of the app is the drug entries. That structure matters more than the raw count of drugs, because it means you can look up a single agent and see the practical details in one place rather than piecing them together from several sources.

The revision also added ten drugs the FDA cleared over the previous year, and it updated the indications for several medicines that were already listed. That is the part of a subscription reference that justifies itself: new approvals and label changes are exactly what a static book cannot keep up with, and the app was updated in September 2025.

Drug-drug interactions and toxicity get their own coverage, which is often the reason someone opens a reference mid-clinic. If a patient is on several agents and you need to check whether a combination raises the risk of a specific toxicity, having that information in the same entry as the dosing is more efficient than consulting two resources.

They will not replace a pharmacology text, but they give a quick anchor for how a class of agents works, which is helpful when explaining a regimen to a trainee or refreshing your own memory before a discussion.

Regimens, antiemetics and the supporting chapters

Beyond individual drugs, the app includes a section on chemotherapy regimens for all the major cancers. This is the part I would expect to be used most often in practice, because treatment is usually delivered as a combination with a name, a schedule and a set of supportive care measures attached. Seeing the regimen as a unit is more useful than reconstructing it from its components.

Supportive care is a large part of what makes chemotherapy tolerable, and having the two phases of nausea and vomiting treated separately in a reference is a sign the content was organized by people who understand the clinical workflow.

There is also a comprehensive discussion of clinical pharmacology alongside the special considerations, indications and dosages, plus the overview of basic cancer drug therapy principles. Together these chapters give the app a textbook layer underneath the quick-reference layer, which is unusual for a mobile drug guide and useful for anyone studying the subject rather than just looking up a dose.

The result is a reference with two speeds: fast lookup for a specific agent or regimen, and slower reading for the pharmacology and principles. How often you use the second part will depend on your role, but its presence makes the app more than a lookup table.

What the subscription costs and how billing works

The app is free to download and carries no ads. The content sits behind an in-app purchase in the form of a subscription priced at $39.99 for one year. The developer says the plan renews every twelve months unless you cancel it, and that your Google Account is charged when you confirm the purchase.

Auto-renewal is the detail to pay attention to. According to the developer, the subscription renews automatically unless auto-renew is turned off at least 24 hours before the end of the current period, and the account is charged $39.99 within 24 hours before that period ends. Subscriptions can be managed and auto-renewal turned off through the Play Store's subscription menu after purchase, and a subscription cannot be cancelled while its term is still running.

For a practicing clinician, $39.99 a year is a modest line item against the cost of most clinical references, and the annual model matches the update cycle: new FDA approvals and revised indications arrive, and the subscription pays for that revision work. It is less obviously good value for a student who needs the material for a single rotation, since the term is a full year.

The free download with no ads means you can install it. The purchase is what opens the reference, and the billing terms are standard for an annual subscription sold through Google Play.

How it compares with other ways of carrying this information

The obvious alternative is a general drug reference app. Those tend to cover a far wider range of medications, which is an advantage if you prescribe across specialties, but they are usually thinner on oncology-specific detail such as regimen schedules, antiemetic protocols and pathway diagrams. The trade-off is breadth against depth, and this app sits firmly on the depth side.

A second option is the print edition of the same manual. A physical book has no subscription, but it cannot absorb ten new FDA approvals and revised indications the way the September 2025 update did. If staying current is the point, the app has the structural advantage; if you want a shelf reference you own outright, the book is the simpler purchase.

Institutional resources are the third comparison. What a phone app adds is portability, which matters on rounds, in clinic rooms and during calls.

None of these alternatives is strictly better. The choice comes down to how much oncology-specific detail you need, whether you want the content to update itself, and whether you are paying personally or through a department budget.

A reference worth carrying for the right clinician

Physicians' Cancer Chemotherapy is a focused professional tool, and it does not pretend otherwise. The catalog of more than 100 agents, the regimen section covering all major cancers, the antiemetic chapter and the pharmacology groundwork add up to a reference that answers the questions an oncology clinician actually asks during a working day. The 4.7 average from 156 ratings and the 10,000-plus installs point to a small audience that finds it useful enough to keep.

The case for installing it rests on two things: you work with cancer drugs regularly, and you want that information to reflect recent approvals and label changes. The $39.99 annual subscription is the cost of that currency. If your oncology work is occasional or your institution already supplies equivalent references, the value is harder to justify.

For oncologists, fellows, advanced practice providers and pharmacists who want a compact, current drug and regimen reference on the device they already carry, this is a reasonable addition to the toolkit. It is not a decision-support system and it is not written for patients; it is a well-organized manual for people who prescribe, dispense and study cancer therapy.

What's new in version 2.3.1.156

Maintenance update